Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Dithiothreitol SCHEMBL27262405 | 1.00 | LMNA (0.42) | LMNATDP1NR1I2ALDH1A1CYP1A2 | |
| Dithiothreitol SCHEMBL28079600 | 1.00 | LMNA (0.42) | LMNATDP1NR1I2ALDH1A1CYP1A2 | |
| Dl-Dithiothreitol SCHEMBL78921 | 0.84 | — | — | |
| Dl-Dithiothreitol SCHEMBL21114401 | 0.84 | LMNA (0.44) | LMNATDP1NR1I2ALDH1A1CYP1A2 | |
| Dl-Dithiothreitol SCHEMBL17370231 | 0.84 | — | — | |
| Dl-Dithiothreitol SCHEMBL14496668 | 0.84 | — | — | |
| Dithiothreitol SCHEMBL538995 | 0.84 | — | — | |
| Dl-Dithiothreitol SCHEMBL21114400 | 0.84 | LMNA (0.44) | LMNATDP1NR1I2ALDH1A1CYP1A2 | |
| Dl-Dithiothreitol SCHEMBL87345 | 0.84 | — | — | |
| Dl-Dithiothreitol SCHEMBL10601 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117929704-A | Detection box for detecting inflammatory bowel disease through fecal sample | 中南大学湘雅医院 | 2024-04-26 | — | — | CN | claimed |
| EP-1666488-B1 | FLUORESCENT PROTEIN | CHISSO CORP (JP) | 2010-11-17 | — | — | EP | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| WO-2005044181-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-05-19 | — | — | WO | claimed |
| US-20220009956-A1 | PREPARATION OF OLIGO CONJUGATES | EMERALD THERAPEUTICS INC (US) | 2022-01-13 | — | — | US | disclosed |
| EP-3819376-A1 | COMPOSITION AND METHOD FOR IMPROVING EFFICIENCY OF SMALL RNA EXTRACTION | Daiyukai Health System (JP) | 2021-05-12 | — | — | EP | disclosed |
| US-20160333045-A1 | Preparation of Oligo Conjugates | Emerald Therapeutics, Inc. | 2016-11-17 | — | — | US | disclosed |
| US-9289502-B2 | Preparation of oligo conjugates | Emerald Therapeutics, Inc. (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2014138373-A1 | PREPARATION OF OLIGO CONJUGATES | Emerald Therapeutics, Inc. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256911-A1 | PREPARATION OF OLIGO CONJUGATES | Emerald Therapeutics, Inc. | 2014-09-11 | — | — | US | disclosed |
| EP-2334748-A1 | PROTEIN/CATIONIC POLYMER COMPOSITIONS HAVING REDUCED VISCOSITY | Hercules Incorporated (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010028062-A1 | PROTEIN/CATIONIC POLYMER COMPOSITIONS HAVING REDUCED VISCOSITY | HERCULES INCORPORATED (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2006084016-A1 | ACID ADDITION SALTS OF Ac-PHSCN-NH2 | ATTENUON, LLC (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005044181-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-05-19 | — | — | WO | disclosed |
| JP-2004315520-A | AUTOIMMUNITY POTENTIATING AGENT, METHOD FOR PRODUCING THE SAME, AND COSMETIC BY USING THE SAME | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL & TECHNOLOGY | 2004-11-11 | — | — | JP | disclosed |
| US-20040058364-A1 | Modified nucleotides and methods useful for nucleic acid sequencing | INVITROGEN CORPORATION | 2004-03-25 | — | — | US | disclosed |
| WO-1999049082-A2 | MODIFIED NUCLEOTIDES AND METHODS USEFUL FOR NUCLEIC ACID SEQUENCING | INVITROGEN CORPORATION (US) | 1999-09-30 | — | — | WO | disclosed |
| US-5897857-A | SULFHYDRYL COMPOUND SELECTED FROM CYSTEINE, HOMOCYCTEINE, GLUTATHIONE, THIOGLYCEROL, THIOMALIC ACID, 2-MERCAPTOETHANOL, MERCAPTOPROPIONIC ACIDS, DITHIOTHREITOL, THIOSALICYLIC ACID, N-ACETYL-L-CYSTEIN AND SALTS; FACIAL HAIR REMOVER | THE PROCTER & GAMBLE COMPANY (US) | 1999-04-27 | — | — | US | disclosed |
| US-RE35500-E | Direct radiolabeling of antibodies and other proteins with technetium or rhenium | ABERLYN CAPITAL MANAGEMENT LIMITED PARTNERSHIP (US) | 1997-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333045-A1 | Preparation of Oligo Conjugates | OSTC, PCBP1, PAICS | LMNA 3846/4885TDP1 2904/4885NR1I2 3056/4885 |
| US-20220009956-A1 | PREPARATION OF OLIGO CONJUGATES | OSTC, PCBP1, PAICS | LMNA 3846/4885TDP1 2904/4885NR1I2 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.